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Abstract
Background: Dual anti-platelet therapy with aspirin and a thienopyridine (DAT) is used to prevent stent
thrombosis after percutaneous coronary intervention (PCI). Low response to clopidogrel therapy (LR) occurs,
but laboratory tests have a controversial role in the identification of this condition.
Methods: We studied LR in patients with stable angina undergoing elective PCI, all on DAT for at least 7 days,
by comparing: 1) Flow cytometry (FC) to measure platelet membrane expression of P-selectin (CD62P) and PAC-
1 binding following double stimulation with ADP and collagen type I either in the presence of prostaglandin (PG)
E1; 2) VerifyNow-P2Y12 test, in which results are reported as absolute P2Y12-Reaction-Units (PRU) or % of
inhibition (% inhibition).
Results: Thirty controls and 52 patients were analyzed. The median percentage of platelets exhibiting CD62P
expression and PAC-1 binding by FC evaluation after stimulation in the presence of PG E1 was 25.4% (IQR: 21.4–
33.1%) and 3.5% (1.7–9.4%), respectively. Only 6 patients receiving DAT (11.5%) had both values above the 1st
quartile of controls, and were defined as LR. Evaluation of the same patients with the VerifyNow-P2Y12 test
revealed that the area under the receiver-operating-characteristic (ROC) curve was 0.94 (95% CI: 0.84–0.98, p
< 0.0001) for % inhibition and 0.85 (0.72–0.93, p < 0.005) for PRU. Cut-off values of ≤ 15% inhibition or > 213
PRU gave the maximum accuracy for the detection of patients defined as having LR by FC.
Conclusion: In conclusion our findings show that a cut-off value of ≤ 15% inhibition or > 213 PRU in the
VerifyNow-P2Y12 test may provide the best accuracy for the identification of patients with LR.
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Background
Thienopyridines such as clopidogrel inhibit P2Y12, one of
two platelet adenosine diphosphate (ADP) receptors
(P2Y1, P2Y12) and have been shown to confer clinical ben-
efit in a variety of conditions characterized by the risk of
arterial thrombosis [1-3]. Nonetheless, in the setting of
coronary artery disease, about 1–1.9% of patients may
experience acute or sub-acute stent thrombosis (ST) after
implantation of a coronary stent [4,5] despite treatment
with clopidogrel in combination with aspirin. Several
mechanisms could explain a low platelet response to
clopidogrel, including poor compliance to treatment, [6]
variable absorption of the drug and/or variable generation
of the active metabolite, and potential drug-drug interac-
tions [7]. Some studies contend that resistance to clopi-
dogrel may be present in as many as 20% of subjects [8-
10]. Patients with a low response to clopidogrel are
known to have an increased risk of cardiovascular events
[11,12]. Thus, there is a clinical need for a reliable test of
platelet response to clopidogrel therapy as a guide to indi-
vidualizing dosing regimens. However, the ideal method
for quantifying inhibition of platelet function by clopi-
dogrel has yet to be agreed upon by the European Society
of Cardiology and American College of Cardiology. Cur-
rent assays which might be considered to be the gold
standard, such as light transmission aggregometry (LTA),
flow cytometric evaluation of platelet activation markers
and flow cytometric measurement of the vasodilator-stim-
ulated phosphoprotein (VASP) phosphorylation status,
are technically complex and restricted to specialized labo-
ratories and therefore none stands out as the clear investi-
gation of choice.
On the other hand, the accuracy of point-of-care assays is
still unclear [13,14]. The VerifyNow-P2Y12  test was
designed to overcome the limitations of conventional
optical platelet aggregation assays. It is a rapid test that
uses ADP to stimulate platelets in the presence of prostag-
landin (PG) E1, which inhibits activation downstream of
a second ADP receptor P2Y1, thus making the assay more
sensitive to the activity of P2Y12. The test can be per-
formed directly in the catheterization laboratory prior to
percutaneous coronary intervention (PCI). However,
there are minimal clinical data on which to define a suit-
able cut-off value for low responders [15-17]. The aim of
our study was to compare the VerifyNow-P2Y12 test with
flow cytometric analysis of platelet activation to define a
cut-off value for low responders to clopidogrel.
Methods
Study population
After obtaining institutional approval and informed con-
sent, we studied 52 consecutive patients aged 64 ± 11
years (mean ± SD) who had evidence of stable coronary
artery disease and were undergoing elective PCI. All
patients studied were on dual anti-platelet therapy (DAT),
100 mg aspirin and 75 mg clopidogrel daily, for at least 7
days prior to testing. Patients who had received intrave-
nous heparin, abciximab, tirofiban, or eptifibatide in the
previous week (typically, patients with acute myocardial
infarction or refractory unstable angina) were excluded
from the study, as were patients with a known platelet
function disorder or a preoperative hematocrit or platelet
count outside the ranges validated for the VerifyNow-
P2Y12 test (33–52% and 119.000–502.000/μL, respec-
tively).
Thirty medication-free volunteers aged 45 ± 16 years, who
were apparently healthy and had no known risk factors for
coronary artery disease, were enrolled from within the
medical staff of our hospital and acted as controls. All
studies involving human subjects were conducted in
accordance with the Declaration of Helsinki.
Platelet Function Analysis
The response to clopidogrel was assessed by flow cytomet-
ric analysis of platelet activation, considered as the refer-
ence standard in this study, and by the VerifyNow-P2Y12
test. Blood specimens were obtained from an antecubital
vein through a clean venipuncture with minimal stasis
using a 19-gauge needle and the double syringe method,
in which the first five mls of blood were discarded to
avoid spontaneous platelet activation [18]. Samples were
processed within 1 hour after venipuncture by two differ-
ent groups of operators. For the VerifyNow-P2Y12 test,
blood was transferred into two 1.8-ml blood collection
tubes containing 0.2 ml buffered 3.2% Na3-citrate solu-
tion (Venoject/Venosafe, Terumo Europe N.V., Leuven,
Belgium) and analyzed after at least 10 minutes and
within 2 hours as suggested by the manufactures.
Flow cytometry analysis of platelet activation
Platelet activation was assessed in platelet-rich plasma
(PRP) as previously described [19] in accordance with the
European Working Group consensus protocol for the flow
cytometric characterization of platelet function. We chose
PRP, rather than whole blood, in order to avoid the poten-
tial for release of ADP by red blood cells which might
stimulate platelet activation. Two mAbs were used: fluo-
rescein isothiocyanate (FITC)-conjugated PAC-1 (Beckton
Dickinson, San Jose, CA), which binds to the activated
conformation of GP IIb-IIIa, and an anti-P selectin mAb
(also known as CD62P)labelled with R-phycoerythrin
(PE) (Caltag Laboratories, Burlingame, CA). P-selectin is
present on the surface of activated but not resting plate-
lets. These two activation markers were analyzed on indi-
vidual platelets in PRP visualized in a flow cytometer
(FC500; Beckman Coulter, S.p.A., Cassina De' Pecchi,
Milan, Italy) before and after double stimulation, for 110
min at room temperature (22–25°C), with 20 μM ADP
(Sigma Chemical Co., St. Louis, MO) and 5 μg/mL equine
tendon collagen type I (Nycomed Pharma GmbH, Ger-Thrombosis Journal 2009, 7:4 http://www.thrombosisjournal.com/content/7/1/4
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many) in presence of 1 μM PG E1 (Sigma) in order to pre-
vent artifact caused by sample manipulation and to
ensure sample stability over time. The ADP/collagen com-
bination acts as a strong stimulus in unstirred PRP, equiv-
alent to α-thrombin that cannot be used because it causes
fibrinogen clotting. Forward light scatter (FS) and side
light scatter (SS) were displayed on logarithmic scales,
and the instrument settings were chosen to highlight the
platelet population that represented >95% of the ele-
ments in PRP. Platelets were also positively identified by
binding of an anti-GP Ibα (CD42b) mAb labeled with
FITC (Immunotech, Marseille Cedex, France). Samples
were analyzed with the acquisition of 20000 events. The
fluorescence of each identified particle was represented on
a log scale. All mAbs were used at saturating concentra-
tions and were incubated for 15 minutes at room temper-
ature after platelet stimulation or in unstimulated PRP.
We did not use fixative solutions because all the ones we
tested contributed to platelet activation and/or interfered
with antibody binding. At the end of the incubation with
antibodies, the samples were diluted with phosphate-
buffered saline (PBS, 0.04 M phosphate buffer and 0.14 M
NaCl, pH 7.4) and immediately analyzed in the flow
cytometer. For all antibodies used, a control antibody of
the same IgG isotype and labelled with the same fluoro-
chrome was incubated with PRP under identical condi-
tions, and platelets were then analyzed to set the lower
limit of positive fluorescence. Results were expressed as
percentage of positive platelets. The conditions described
here are not standard reference conditions. Rather, these
are standardized conditions chosen by our laboratory to
ensure internal reproducibility.
VerifyNow-P2Y12 assay
The VerifyNow-P2Y12 test cartridge system (Accumetrics,
San Diego, CA, USA; in Italy distributed by Endotech
S.P.A., Como) was used as described previously [20]. This
is a rapid (less than 5 minutes) platelet function assay
designed to measure directly the effects of drugs on the
P2Y12 receptor. The assay is a turbidimetric-based optical
detection system that, like optical aggregometry, depends
on the ability of activated platelets to bind fibrinogen. The
assay contains 20 μmol ADP and 22 nmol PG E1 to reduce
the activation contribution from ADP binding to P2Y1
receptors, thus making the assay specific for the effects of
ADP mediated by P2Y12. The test is designed to measure
platelet P2Y12 receptor blockade in patients already receiv-
ing clopidogrel, whose treatment cannot be discontinued
solely to obtain a baseline level of platelet activity. Thus,
the latter parameter (BASE) is determined using a modi-
fied thrombin receptor activating peptide (iso-TRAP) in a
reference channel. The results of the assay (TEST) are
reported as absolute P2Y12-Reaction-Units (PRU) as well
as percent inhibition (% inhibition), the latter calculated
as 100 - (TEST/BASE × 100) or [(BASE - TEST)/BASE] ×
100.
Evaluation of "Controls" and definition of "Low response" 
to clopidogrel at Flow Cytometry
In healthy volunteers, the median percentages of platelets
stimulated in the presence of PG E1 that expressed CD62P
was 25.4% (IQR: 21.4–33.1%). The corresponding values
for PAC-1 binding were 3.5% (IQR: 1.7–9.4%). CD62P
expression and PAC-1 binding showed no correlation
with age (Spearman r = 0.17 and 0.16, respectively). The
median percentages of platelets exhibiting CD62P expres-
sion and PAC-1 binding in controls aged >30 years (54 ±
12.4, mean ± SD) or <30 years (27 ± 2, mean ± SD) were
24% vs. 23.6% and 4.8% vs. 2.1%, respectively, and were
not significantly different.
A patient was defined as a "Low-responder" to clopidogrel
when the percentages of platelets exhibiting CD62P
expression and PAC-1 binding were both above the 1st
quartile of normal distribution (21.4% and 1.7%, respec-
tively); and as a "High-responder" when both values were
below the 1st quartile of normal. The remaining patients
(with percentage of platelets expressing CD62P above the
1st quartile of normal but percentage of PAC-1 binding
platelets below the 1st quartile of normal, or vice versa)
were considered an "Intermediate-responder" to clopidog-
rel.
Statistics
The results of the assays were not normally distributed, as
verified using the Kolmogorov-Smirnov test. Thus they are
reported here as median and interquartile range (IQR)
unless otherwise stated. Differences between groups were
analyzed with the Mann-Whitney test and Spearman or
Pearson testing was appropriately performed for correla-
tion analysis between variables. The diagnostic value of
the VerifyNow-P2Y12 test was assessed by calculating the
area under receiver-operating characteristic (ROC) curves
which plot sensitivity (true-positive fraction) versus 1-spe-
cificity (where the latter is the false-positive fraction) for a
range of results [21]. The values of PRU and % inhibition
yielding the highest accuracy (maximal true positive and
minimal false positive results, where positive was defined
by the results of the flow cytometric assay) where chosen
as cut-off limits of the VerifyNow-P2Y12 test. Statistical
analyses were performed using SPSS 16 (SPSS, Inc., Chi-
cago, Illinois), MEDCALC 9.3 (MedCalc Software, Mari-
akerke, Belgium) and GraphPad 5.00 (GraphPad
Software, San Diego, California). All statistical tests were
two-tailed and p values < 0.05 were considered signifi-
cant.
Results
Flow Cytometry
Fifty-two patients (age, 64 ± 11 years, mean ± SD) were
tested and their clinical characteristics are reported in
Table 1. By flow cytometric analysis, the percentages of
platelets that expressed CD62P or bound PAC-1 (medianThrombosis Journal 2009, 7:4 http://www.thrombosisjournal.com/content/7/1/4
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and IQR) were 11.9% (1.8–43%) and 1.8% (0.1–8%)
respectively, both significantly lower (p < 0.0002 and p <
0.007, respectively) than the corresponding values in nor-
mal controls. Among the patients, six (11.5%) exhibited
both CD62P expression and PAC-1 binding above the 1st
quartile of normal (median and IQR: 29.5%, 23.4–
42.9%; and 4.4%, 2.3–7.9%, respectively). These six
patients were therefore defined as low-responders to
clopidogrel. In contrast, 23 patients (44.2%) exhibited
both CD62P expression and PAC-1 binding below the 1st
quartile of normal (median and IQR: 7.8%, 1.8–19.7%;
and 0.8%, 0.1–1.7%, respectively) and were defined as
high-responders to clopidogrel. The remaining 23
patients (44.2%) were defined as intermediate respond-
ers, due to a high (above the 1st quartile of normal) per-
centage of platelets expressing CD62P and a low (below
the 1st quartile of normal) percentage of platelets binding
PAC-1 (2 patients, 3.8%) or vice versa (21 patients,
40.3%). There were no differences in baseline clinical
characteristics between patients defined as low-respond-
ers to clopidogrel versus intermediate plus high-
responder patients, (Table 2).
As expected, the median values of CD62P expression and
PAC-1 binding in patients were significantly lower than in
controls only in high responders (p < 0.0001) and inter-
mediate responders (p < 0.0001 and p < 0.02, respec-
tively).
VerifyNow-P2Y12 test
With the VerifyNow-P2Y12 test, the six patients defined as
low-responders to clopidogrel by flow cytometric analysis
of platelet activation gave a median % inhibition value of
9.5% (IQR: 9–11.5%). In contrast, the 23 patients defined
as high-responders gave a median % inhibition value of
43% (IQR: 34–68%). The differences between these
results was significant (p < 0.0007). The area under the
ROC curve for the VerifyNow-P2Y12 test values expressed
as % inhibition was 0.94 (95% confidence interval, 0.84–
0.98; p < 0.0001; Figure 1). From the ROC curve analysis,
a cut-off of ≤ 15% inhibition gave the maximum accuracy
(sensitivity 100%; specificity 89.1%). Considering the
same results expressed as absolute PRU, the area under the
ROC curve was 0.85 (95% confidence interval, 0.72–0.93;
p < 0.005; Figure 1) with a cut-off for accuracy of > 213
(sensitivity 83.3%; specificity 84.4%).
All six patients (11.5%) defined as low-responders on the
basis of CD62P expression and PAC-1 binding were lower
or equal to 15% inhibition, and all 23 patients (44.2%)
defined as high-responders were above 15% inhibition
(Figure 2 and 3). Of the remaining 23 (44.2%) patients
defined as intermediate responders, five were below 15%
inhibition; in all these individuals, the percentage of
platelets expressing CD62P was below or equal the 1st per-
centile of normal controls (Figure 2), but that of platelets
binding PAC-1 was above (Figure 3). In total 11 patients
(21%) were lower or equal to 15% inhibition and as a
result low clopidogrel responders.
Finally, a good correlation was found between % inhibi-
tion and the percentages of platelets that expressed
CD62P or bound PAC-1 (Spearman r = -0.67, p < 0.0001;
and -0.49, p < 0.002, respectively; Figure 2).
Discussion
A simple test such as the VerifyNow-P2Y12 test may be use-
ful to monitor the response to antiplatelet therapy and
offers the possibility of a point-of-care approach, e.g. to
assess whether the response to a clopidogrel loading dose
is adequate in patients undergoing coronary stenting. As
relevant as the simplicity of its use is, the correct interpre-
tation of results remains of paramount importance to
make appropriate therapeutic decisions. According to the
manufacturer, the initial proposed cut-off value to dis-
criminate patients with a low response to clopidogrel
Table 1: Baseline Clinical Characteristics of 52 Patients.
N (%) or mean ± SD
Age (years) 64 ± 11
Male 39 (75)
Ejection fraction % 53 ± 8
Body mass index >30, kg/m2 7 (15)
Hematocrit % 36.6 ± 8.3
Platelet count (× 103/μL) 251 ± 127
Risk Factors
Diabetes 14 (28)
-Insulin dependent Diabetes 6 (12)
Hypertension 32 (64)
Hypercholesterolemia 31 (62)
Current smoking 5 (10)
History
Previous MI 23 (46)
Previous PCI 16 (48)
Previous CABG 6 (12)
Chronic renal failure† 2 (4)
Coronary Artery Disease n, (%)
1 vessel 12 (28)
2 vessel 29 (55)
3 vessel 18 (34)
Therapy n, (%)
Beta-blockers 32 (61)
ACE-inhibitors 30 (57)
Nitrates 10 (19)
Ca-antagonists 17 (32)
Statins 38 (71)
Values are expressed as means ± SDs or number (percentages) of 
patients.
MI = acute myocardial infarction; PCI = percutaneous coronary 
intervention; CABG = coronary artery bypass graft. †Defined as the 
presence of previously documented renal failure and/or a baseline 
serum creatinine level > 2 mg/dl.Thrombosis Journal 2009, 7:4 http://www.thrombosisjournal.com/content/7/1/4
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using the VerifyNow-P2Y12 test was 50% inhibition (not
specified in the user manual, only suggested informally).
Using such a value, we were surprised to find that an unex-
pectedly high 75% of our 52 patients treated with DAT
were defined as low clopidogrel responders. We consid-
ered this as unlikely and sought to verify the validity of the
proposed cut-off limit. Indeed, by using markers of plate-
let activation measured by flow cytometry to define low
responders, we found by ROC curve evaluation that a %
inhibition ≤ 15 and absolute PRU > 213 may be Veri-
fyNow-P2Y12 cut-off values that identify patients with low
response to clopidogrel with maximum sensitivity and
specificity. Using the ≤ 15% inhibition limit that we estab-
lished, only 21% of our 52 patients receiving conven-
tional clopidogrel treatment were classified as low
responders (and 23% using the PRU > 213 limit). This
result is in agreement with other studies that have shown
resistance to clopidogrel may be present in as many as
20% of subjects [8,10,22]. Recently, Lordkipanidzé et al.
[23] suggested that the assay-reported % inhibition of
platelets fails to accurately quantify inhibition achieved
by clopidogrel, as TRAP-induced aggregation may not
adequately mimic off-drug ADP/PGE1-induced aggrega-
tion. We have therefore described the usefulness of both
the PRU value and the % inhibition value for detecting
'low responders' in this manuscript.
In the present study, the reliability of both cut-off values
was shown to be high on ROC curve analysis, with the
value for % inhibition shown to have a 100% sensitivity
for detecting low responders as defined by flow cytometry,
a finding that contrasts with the results obtained in the
work by Lordkipanidzé et al. [23]. This emphasises the
importance of further published studies in this area, as
establishing the reliability of each assay may not be as
straight forward as first appears. Whilst the accuracy of the
% inhibition value quoted by the VerifyNow-P2Y12 test
remains to be clarified, there are now several clinical stud-
ies which show that a high PRU obtained with this assay
is associated with adverse clinical consequences. For
example, in a large clinical study of 380 PCI patients, a
high PRU was strongly associated with adverse clinical
outcomes, including stent thrombosis (p = 0.004) and
furthermore was associated with the hardest of clinical
endpoints – cardiovascular death (p = 0.04) [15]. Subse-
quent publications have confirmed the usefulness of the
VerifyNow assay in predicting adverse clinical events
[16,17]. The usefulness of our lab cut-off value of PRU >
213 should be considered in conjunction with other pub-
lished cut-offs proven be of clinical significance, such as
those identified by Price et al. (PRU > 235) [15] and Patti
et al. (PRU > 240) [16]. From these data, we can infer that
whilst the % inhibition value remains of interest, the PRU
value (a direct measure of platelet aggregation induced by
either ADP/PGE1) may be a more reliable method of
identifying subjects who are hyporesponsive to clopidog-
rel therapy and subsequently at risk of clinical events.
The validity of our conclusions is entirely dependent on
the definition of resistance to anti-platelet therapy, for
which we relied on the measurement of two platelet acti-
vation markers by flow cytometric analysis. Flow cytome-
try, similarly to light transmission aggregometry (LTA), is
used by specialized laboratories and represents a reference
standard for the assessment of platelet function [13,14].
In this regard, LTA is the most widely used method but has
well-known limitations, including poor reproducibility,
high sample volume, requirement for sample preparation,
length of assay time, requirement for a skilled technician,
Table 2: Correlation analysis of variables and clopidogrel low response.
Variables Low Responder patients*
N = 6
Intermediate plus High Responder patients*
N = 46
P value
Age 62 ± 13.2 64 ± 10.7 0.671
Male 4 (66) 35 (76) 0.472
Body mass index, kg/m2 26 ± 3.3 26 ± 4.3 0.956
Ejection fraction % 54 ± 3.7 52 ± 9.6 0.652
Hematocrit % 36.2 ± 7.8 37 ± 8 0.774
Platelet count (× 103/μL) 268 ± 124 235 ± 130 0.439
Current smoking 1 (17) 4 (87) 0.487
Diabetes 1 (17) 13 (29.5) 0.663
-Insulin dependent Diabetes 0 6 (15) 0.444
Chronic renal failure 0 2 (43) 0.772
Hypertension 3 (50) 29 (63) 0.369
Hypercholesterolemia 3 (50) 28 (61) 0.412
Statins 6 (100) 32 (70) 0.136
CYP3A4-metabolizing statins 5 (83) 23 (50) 0.134
Values are expressed as means ± SDs or number (percentages) of patients.
*Defined by flow cytometric evaluation of platelet activation parameters.Thrombosis Journal 2009, 7:4 http://www.thrombosisjournal.com/content/7/1/4
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and cost [13]. Therefore, new options for platelet function
testing have been developed to address these disadvan-
tages and to meet the need for point-of-care testing that
can be performed at or near a patient's bedside without
requiring a high degree of technical expertise. The new
tests include VerifyNow (Accumetrics, San Diego, CA);
Plateletworks (Helena Laboratories, Beaumont, TX);
Thrombelastograph PlateletMapping System (Haemo-
scope Corporation, Niles, IL); Impact cone and plate(let)
analyzer (DiaMed, Cressier, Switzerland); and Platelet
Function Analyzer 100 (PFA-100; Dade Behring, Newark,
DE) [13]. However, the relationship of in vivo platelet
function and adverse clinical events to results of ex vivo
platelet function tests remains largely unknown [24].
Aggregation assays are influenced by GP IIb-IIIa function
downstream of the outside-in signals generated by platelet
agonists, including ADP, and are dependent as well on
inside-out signals required for activation of the integrin.
For these reasons, which may confound the interpretation
of the functional state of P2Y12, we elected to measure sur-
face translocation of P-selectin as an activation marker
possibly more directly linked to ADP-induced platelet
stimulation, as well as PAC-1 binding that, by reflecting
GP IIb-IIIa activation, provides information consistent
with that of aggregation assays. In order to obtain strong
platelet stimulation, a desirable condition to study the
effect of anti-platelet drugs, we used a combination of
ADP and collagen to activate two distinct signalling path-
ways. Moreover, we stimulated platelets in the presence of
PG E1, a condition occurring in the VerifyNow-P2Y12 test
as well, with the intent of inhibiting signalling down-
stream of the P2Y1 ADP receptor and highlighting the
functional state of P2Y12, which is the specific target of
thienopyridines such as clopidogrel [25]. Of note, the use
of PG E1  is not compatible with aggregation studies.
CD62P expression and PAC-1 binding appeared equally
useful as indicators of the effects of anti-platelet treat-
ment. Because we collected blood specimens with the
addition of PG E1 (to prevent post-sampling artefacts) we
Receiver Operator Characteristic (ROC) curves defining the sensitivity and specificity of the VerifyNow-P2Y12 test in patients  receiving antiplatelet therapy Figure 1
Receiver Operator Characteristic (ROC) curves defining the sensitivity and specificity of the VerifyNow-P2Y12 
test in patients receiving antiplatelet therapy. Sensitivity and specificity in discriminating responders from non-respond-
ers to treatment was based on the arbitrary definition of positive patients (Low responders to clopidogrel; n = 6) and negative 
patients (High plus Intermediate responders to clopidogrel; n = 46) based on the percentage of platelets exhibiting CD62P 
expression and PAC-1 binding after stimulation in the presence of PG E1. The two curves shown here, for results expressed as 
PRU (absolute P2Y12 Reaction Unit) and % of inhibition (% inhibition), respectively, define cut-off values of PRU > 213 and ≤ 
15% inhibition, as those giving the highest accuracy (minimal false negative and positive results) in the VerifyNow-P2Y12 test.Thrombosis Journal 2009, 7:4 http://www.thrombosisjournal.com/content/7/1/4
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could verify that, in spite of the presence of this inhibitor,
dual agonist-induced activation still caused an enhance-
ment of activation markers, and the difference between
normal controls and patients with stable coronary artery
disease receiving anti-platelet drugs remained highly sig-
nificant.
Study limitations
A possible limitation of our study may be the use of the
first quartile in a relatively small sample of normal popu-
lation as a discriminator for low responders. Conse-
quently, our results must be viewed only as a first step,
albeit necessary, towards prospective studies (in a very
large series of patients) with clinical end-points aimed at
establishing therapeutic efficacy in relation to the results
of laboratory tests. It is noteworthy, in this regard, that
measuring the surface translocation of P-selectin in plate-
lets stimulated in the presence of PG E1 appears to be
more sensitive to the therapeutic inhibition of P2Y12 than
measuring GP IIb-IIIa activation (as reflected by PAC-1
binding). In fact, several patients treated with the aspirin/
clopidogrel combination had levels of P-selectin surface
translocation below the 1st quartile of normal values when
PAC-1 binding was above this limit. Such experimental
evidence is compatible with a potential lower sensitivity
of aggregation assays to the effects of clopidogrel treat-
ment, while stressing the difficulty of choosing a labora-
tory test for monitoring therapy without the benefit of
clinical information.
Previous studies [26] have compared the VerifyNow-
P2Y12 test (reporting only absolute PRU) with LTA, but
without addressing the question of the optimum cut-off
values to discriminate responders from non-responders
among patients receiving anti-platelet therapy. Our results
show that, in this regard, the accuracy of the VerifyNow-
P2Y12 test is comparable to that of measuring platelet acti-
vation markers by flow cytometry, and provide a calibra-
tion of the test with the definition of more realistic cut-off
values to judge the efficacy of treatment. Another limita-
Correlation between the results obtained by flow cytometric evaluation of platelet activation parameters and VerifyNow- P2Y12 test in patients receiving antiplatelet therapy Figure 2
Correlation between the results obtained by flow cytometric evaluation of platelet activation parameters and 
VerifyNow-P2Y12 test in patients receiving antiplatelet therapy. The percent of inhibition (% inhibition) was plotted 
against the percentage of platelets that expressed P-selectin (CD62P) after stimulation with 20 μM ADP and 5 μg/mL collagen 
type I for 110 min at room temperature in the presence of 1 μM PG E1. (§) First quartile of control values for CD62P expres-
sion. Patients receiving antiplatelet therapy with levels of CD62P expression and PAC-1 binding above this limit were defined 
as "Low-responder"; those with both values below this limit were defined as "High-Responder"; those with one value above and 
the other below the corresponding limit were defined as "Intermediate-responder". ($) Cut-off value for % of inhibition in the 
VerifyNow-P2Y12 test giving minimal false negative and positive results (see Figure 1).Thrombosis Journal 2009, 7:4 http://www.thrombosisjournal.com/content/7/1/4
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tion is that we did not evaluate possible improvements in
patients with a low % inhibition following a higher dos-
age of clopidogrel. Our aim, nonetheless, was to validate
an assay and establish an initial "reference value" in view
of future prospective studies.
Conclusion
In conclusion, these results provide information on the
cut-off values, using the VerifyNow-P2Y12 test, that iden-
tify patients with a low response to antiplatelet therapy. A
% of inhibition ≤ 15% and absolute PRU > 213 appear to
reflect low platelet inhibition.
Abbreviations
ADP: adenosine diphosphate; PG: prostaglandin; PCI:
percutaneous coronary intervention; PRU: P2Y12 reactive
units;  CD62P: P-selectin; mAb: monoclonal antibody;
GP: glycoprotein; PRP: platelet-rich plasma; FITC: fluores-
cein isothiocyanate; PE: R-phycoerythrin; FS: forward
light scatter; SS: side light scatter; CD42b: GP Ibα; TRAP:
thrombin receptor activating peptide; IQR: interquartile
range; ROC: receiver operating characteristic; LTA: light
transmission aggregometry.
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